查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1387324

全球抗生素抗藥性市場：趨勢、預測和競爭分析（~2030 年）

Antibiotic Resistance Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

抗生素抗藥性趨勢和預測

預計到2030年，全球抗生素抗藥性市場規模將達到約122億美元，2024年至2030年年複合成長率為5.9%。該市場的主要促進因素是抗生素的日益普及以及政府和非政府組織擴大參與新治療方法的開發。全球抗生素抗藥性市場前景廣闊，醫院藥局、零售藥局、線上藥局市場蘊藏商機。

抗生素抗藥性市場洞察

Lucintel 預計，由於有強大的產品開發平臺，cUTI（複雜尿道感染）在預測期內仍將是最大的細分市場。

醫院藥劑師將繼續成為該市場中最大的部分，因為他們在監督藥物處方、追蹤抗藥性模式、提供教育和確保藥物安全方面發揮關鍵作用。

由於該地區政府計劃和強制保險政策的增加，北美在預測期內將繼續成為最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球抗生素抗藥性市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢與預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球抗生素抗藥性市場趨勢（2018-2023）與預測（2024-2030）
  • 全球抗生素抗藥性市場：依疾病分類
    • cUTI (Complicated Urinary Tract Infections)
    • CDI (Clostridioides difficile Infection)
    • ABSSSI (Acute bacterial skin and skin structure infections)
    • HABP (Hospital-acquired bacterial pneumonia)
    • CABP (Community-acquired pneumonia)
    • cIAI (Complicated intra-abdominal infection)
    • 其他
  • 全球抗生素抗藥性市場：依病原體分類
    • E. Coli
    • K. Pneumoniae
    • P. Aeruginosa
    • S. Aureus
    • A. Baumannii
    • S. Pneumoniae
    • 其他
  • 全球抗生素抗藥性市場：按配銷通路
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 全球抗生素抗藥性市場：按作用機制
    • Protein Synthesis Inhibitors
    • Cell Wall Synthesis Inhibitors
    • RNA Synthesis Inhibitors
    • DNA Synthesis Inhibitors
    • 其他

第4章 市場趨勢與預測分析：按地區（2018-2030）

  • 全球抗生素抗藥性市場：按地區
  • 北美抗生素抗藥性市場
  • 歐洲抗生素抗藥性市場
  • 亞太地區抗生素抗藥性市場
  • 其他地區抗生素抗藥性市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按疾病分類的全球抗生素抗藥性市場成長機會
    • 病原體的全球抗生素抗藥性市場成長機會
    • 按配銷通路的全球抗生素抗藥性市場成長機會
    • 按作用機制分類的全球抗生素抗藥性市場成長機會
    • 全球抗生素抗藥性市場成長機會（按地區）
  • 全球抗生素抗藥性市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球抗生素抗藥性市場產能擴張
    • 全球抗生素抗藥性市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Melinta
  • Basilea Pharmaceutical
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • WOCKHARDT
簡介目錄

Antibiotic Resistance Trends and Forecast

The future of the global antibiotic resistance market looks promising with opportunities in the hospital pharmacie, retail pharmacie and online pharmacie markets. The global antibiotic resistance market is expected to reach an estimated $12.2 billion by 2030 with a CAGR of 5.9% from 2024 to 2030. The major drivers for this market are increasing prevalence of antibiotic and growing government and non-government bodies involvement in the development of novel therapies.

A more than 150-page report is developed to help in your business decisions.

Antibiotic Resistance by Segment

The study includes a forecast for the global antibiotic resistance by disease, pathogen, distribution channel, mechanism of action, and region.

Antibiotic Resistance Market by Disease [Shipment Analysis by Value from 2018 to 2030]:

  • cUTI (Complicated Urinary Tract Infections)
  • CDI (Clostridioides Difficile Infection)
  • ABSSSI (Acute Bacterial Skin and Skin Structure Infections)
  • HABP (Hospital-Acquired Bacterial Pneumonia)
  • CABP (Community-Acquired Pneumonia)
  • cIAI (Complicated Intra-Abdominal Infection)
  • Others

Antibiotic Resistance Market by Pathogen [Shipment Analysis by Value from 2018 to 2030]:

  • E. Coli
  • K. Pneumoniae
  • P. Aeruginosa
  • S. Aureus
  • A. Baumannii
  • S. Pneumoniae
  • Others

Antibiotic Resistance Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Antibiotic Resistance Market by Mechanism of Action [Shipment Analysis by Value from 2018 to 2030]:

  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Others

Antibiotic Resistance Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Antibiotic Resistance Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies antibiotic resistance companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antibiotic resistance companies profiled in this report include-

  • Melinta
  • Basilea Pharmaceutical
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • WOCKHARDT

Antibiotic Resistance Market Insights

Lucintel forecasts that cUTI (complicated urinary tract infection) will remain the largest segment over the forecast period due to existence of a robust product development pipeline.

Within this market, hospital pharmacie will remain the largest segment as it plays a vital role in overseeing drug formularies, tracking resistance patterns, delivering education, and guaranteeing medication safety.

North America will remain the largest region over the forecast period due to increasing number of government programs and mandatory insurance policies in the region.

Features of the Global Antibiotic Resistance Market

Market Size Estimates: Antibiotic resistance market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Antibiotic resistance market size by various segments, such as by disease, pathogen, distribution channel, mechanism of action, and region in terms of value ($B).

Regional Analysis: Antibiotic resistance market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different diseases, pathogens, distribution channels, mechanism of actions, and regions for the antibiotic resistance market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antibiotic resistance market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the antibiotic resistance market size?

Answer: The global antibiotic resistance market is expected to reach an estimated $12.2 billion by 2030.

Q2. What is the growth forecast for antibiotic resistance market?

Answer: The global antibiotic resistance market is expected to grow with a CAGR of 5.9% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the antibiotic resistance market?

Answer: The major drivers for this market are increasing prevalence of antibiotic and growing government and non-government bodies involvement in the development of novel therapies.

Q4. What are the major segments for antibiotic resistance market?

Answer: The future of the antibiotic resistance market looks promising with opportunities in the hospital pharmacie, retail pharmacie and online pharmacie markets.

Q5. Who are the key antibiotic resistance market companies?

Answer: Some of the key antibiotic resistance companies are as follows:

  • Melinta
  • Basilea Pharmaceutical
  • Tetraphase Pharmaceuticals
  • Theravance Biopharma
  • WOCKHARDT

Q6. Which antibiotic resistance market segment will be the largest in future?

Answer: Lucintel forecasts that cUTI (complicated urinary tract infection) will remain the largest segment over the forecast period due to existence of a robust product development pipeline.

Q7. In antibiotic resistance market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing number of government programs and mandatory insurance policies in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the antibiotic resistance market by disease (cUTI (complicated urinary tract infections), CDI (clostridioides difficile infection), ABSSSI (acute bacterial skin and skin structure infections), HABP (hospital-acquired bacterial pneumonia), CABP (community-acquired pneumonia), CIAI (complicated intra-abdominal infection), and others), pathogen (e. coli, k. pneumoniae, p. aeruginosa, s. aureus, a. baumannii, s. pneumoniae, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), mechanism of action (protein synthesis inhibitors, cell wall synthesis inhibitors, rna synthesis inhibitors, dna synthesis inhibitors, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Antibiotic Resistance Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Antibiotic Resistance Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Antibiotic Resistance Market by Disease
    • 3.3.1: cUTI (Complicated Urinary Tract Infections)
    • 3.3.2: CDI (Clostridioides difficile Infection)
    • 3.3.3: ABSSSI (Acute bacterial skin and skin structure infections)
    • 3.3.4: HABP (Hospital-acquired bacterial pneumonia)
    • 3.3.5: CABP (Community-acquired pneumonia)
    • 3.3.6: cIAI (Complicated intra-abdominal infection)
    • 3.3.7: Others
  • 3.4: Global Antibiotic Resistance Market by Pathogen
    • 3.4.1: E. coli
    • 3.4.2: K. pneumoniae
    • 3.4.3: P. aeruginosa
    • 3.4.4: S. aureus
    • 3.4.5: A. baumannii
    • 3.4.6: S. pneumoniae
    • 3.4.7: Others
  • 3.5: Global Antibiotic Resistance Market by Distribution Channel
    • 3.5.1: Hospital Pharmacies
    • 3.5.2: Retail Pharmacies
    • 3.5.3: Online Pharmacies
  • 3.6: Global Antibiotic Resistance Market by Mechanism of Action
    • 3.6.1: Protein Synthesis Inhibitors
    • 3.6.2: Cell Wall Synthesis Inhibitors
    • 3.6.3: RNA Synthesis Inhibitors
    • 3.6.4: DNA Synthesis Inhibitors
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Antibiotic Resistance Market by Region
  • 4.2: North American Antibiotic Resistance Market
    • 4.2.2: North American Antibiotic Resistance Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.3: European Antibiotic Resistance Market
    • 4.3.1: European Antibiotic Resistance Market by Disease: cUTI (Complicated Urinary Tract Infections), CDI (Clostridioides difficile Infection), ABSSSI (Acute bacterial skin and skin structure infections), HABP (Hospital-acquired bacterial pneumonia), CABP (Community-acquired pneumonia), cIAI (Complicated intra-abdominal infection), and Others
    • 4.3.2: European Antibiotic Resistance Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.4: APAC Antibiotic Resistance Market
    • 4.4.1: APAC Antibiotic Resistance Market by Disease: cUTI (Complicated Urinary Tract Infections), CDI (Clostridioides difficile Infection), ABSSSI (Acute bacterial skin and skin structure infections), HABP (Hospital-acquired bacterial pneumonia), CABP (Community-acquired pneumonia), cIAI (Complicated intra-abdominal infection), and Others
    • 4.4.2: APAC Antibiotic Resistance Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.5: ROW Antibiotic Resistance Market
    • 4.5.1: ROW Antibiotic Resistance Market by Disease: cUTI (Complicated Urinary Tract Infections), CDI (Clostridioides difficile Infection), ABSSSI (Acute bacterial skin and skin structure infections), HABP (Hospital-acquired bacterial pneumonia), CABP (Community-acquired pneumonia), cIAI (Complicated intra-abdominal infection), and Others
    • 4.5.2: ROW Antibiotic Resistance Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Antibiotic Resistance Market by Disease
    • 6.1.2: Growth Opportunities for the Global Antibiotic Resistance Market by Pathogen
    • 6.1.3: Growth Opportunities for the Global Antibiotic Resistance Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Antibiotic Resistance Market by Mechanism of Action
    • 6.1.5: Growth Opportunities for the Global Antibiotic Resistance Market by Region
  • 6.2: Emerging Trends in the Global Antibiotic Resistance Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Antibiotic Resistance Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Antibiotic Resistance Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Melinta
  • 7.2: Basilea Pharmaceutical
  • 7.3: Tetraphase Pharmaceuticals
  • 7.4: Theravance Biopharma
  • 7.5: WOCKHARDT